The group, which argues that opioid labeling is overly broad, is pushing for the FDA to remove the word “moderate” from the description that describes drugs as approved for “moderate to severe pain.”
Among those who signed the petition are members of Physicians for Responsible Opioid Prescribing and physicians or researchers with the New York City Health Commissioner, the Cleveland Clinic and the Mayo Clinic.
Related Articles on Pain Management:
Orexo Seeks FDA Approval for Opioid Dependency Drug
Nektar Launches Phase 2 Study for Chronic Pain Drug
Relmada Raises $3M to Develop LevoCap Painkiller
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
